Quarterly report [Sections 13 or 15(d)]

Fair Value of Financial Instruments - Narrative (Details)

v3.26.3
Fair Value of Financial Instruments - Narrative (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
$ / shares
shares
Sep. 30, 2025
USD ($)
$ / shares
Sep. 30, 2026
USD ($)
$ / shares
shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
shares
Feb. 25, 2025
shares
Sep. 30, 2021
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]              
Interest income | $ $ 3,800   $ 5,000        
Warrants outstanding (in shares)         2,633,195 5,098,978  
Increase (decrease) in fair value | $     $ 14,147        
Common Stock              
Subsidiary, Sale of Stock [Line Items]              
Common issued for warrants exercised (in shares) 52,983   1,252,954 9,499,138      
Private Warrants              
Subsidiary, Sale of Stock [Line Items]              
Warrants outstanding (in shares) 0   0   2,633,195   7,732,168
Number of warrants to purchase common stock (in shares)             1
Fair value (in dollars per share) | $ / shares $ 11.50 $ 11.50 $ 11.50 $ 11.50     $ 11.50
Increase (decrease) in fair value | $ $ (600) $ (14,200) $ 14,147 $ (11,500)      
Class of warrants exercised (in shares) 130,000   2,430,000 4,631,799      
Warrants exercised (in shares) 0   0 467,174      
Exercise price convertible ratio 1   1        
Proceeds from common stock issued for warrants exercise | $ $ 400   $ 1,900 $ 5,400      
Private Warrants | Common Stock              
Subsidiary, Sale of Stock [Line Items]              
Common issued for warrants exercised (in shares) 15,915   1,084,766 2,293,739      
Warrants exercised (in shares)       467,174